Information Provided By: 
Fly News Breaks for February 7, 2020
ABBV
Feb 7, 2020 | 13:20 EDT
Piper Sandler analyst Christopher Raymond raised his price target for AbbView to $97 from $95 and maintained an Overweight rating following the company's "nice" Q4 report, with beats on the top- and bottom-lines. As the focus shifts to label expansion for growth products, and with a number of clinical proof-of-concept updates expected from the pipeline this year, Raymond tells investors in a research note that he continues to like the setup on this name.
News For ABBV From the Last 2 Days
There are no results for your query ABBV
